JOHN GUERRERO: Open Payments
NPI 1154801280 · EL CENTRO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$715 in 31 payments from 13 companies in 2025. Trend: 2023 $430 · 2024 $592 · 2025 $715
Food & beverage: $715
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 11 | $232 |
| GENZYME CORPORATION | 3 | $107 |
| SHIELD THERAPEUTICS INC | 2 | $57 |
| AstraZeneca Pharmaceuticals LP | 2 | $46 |
| Amgen Inc. | 2 | $43 |
| Corcept Therapeutics | 2 | $42 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $41 |
| GlaxoSmithKline, LLC. | 1 | $33 |
| Lilly USA, LLC | 2 | $32 |
| Insulet Corporation | 1 | $25 |
Products named: Ozempic, DUPIXENT, ACCRUFER, OTEZLA, Korlym, Kerendia, TRELEGY ELLIPTA, Wegovy.
Industry payments across CA — which companies pay providers there.
